What is Surf Bio?
Surf Bio operates as a preclinical biopharmaceutical enterprise, utilizing a sophisticated biotechnology platform to refine therapeutic solutions across diverse medical domains, including oncology, diabetes, and infectious diseases. Founded by industry veterans from Bigfoot Biomedical and Mode AGC, the company commercializes breakthrough stabilization technology originating from the Appel Lab. The core value proposition lies in its ability to reduce reliance on cold-chain logistics and facilitate the transition of complex treatments from intravenous administration to more convenient subcutaneous delivery methods. This technological edge allows for the development of novel formulations that address significant unmet needs in modern medicine, effectively bridging the gap between laboratory discovery and clinical application.
How much funding has Surf Bio raised?
Surf Bio has raised a total of $16M across 1 funding round:
Angel/Seed
$16M
Angel/Seed (2022): $16M with participation from Breakout Ventures and Perceptive Xontogeny Venture Fund
Key Investors in Surf Bio
Breakout Ventures
Breakout Ventures is a venture capital firm focused on investing in transformative companies that leverage scientific innovation and technology to create new markets.
Perceptive Xontogeny Venture Fund
A specialized investment vehicle focused on early-stage life sciences companies, providing both capital and operational expertise to accelerate drug development.
What's next for Surf Bio?
With this major enterprise-level funding, Surf Bio is poised to accelerate its research and development pipeline, focusing on the scalability of its stabilization technology. The strategic roadmap involves transitioning key assets toward clinical trials while expanding the application of its platform to include gene therapy and other complex biologics. By optimizing pharmaceutical formulations, the company aims to disrupt existing treatment paradigms, potentially reducing healthcare costs and improving patient compliance. Future growth will likely center on strategic partnerships with larger pharmaceutical entities seeking to modernize their drug portfolios, as Surf Bio continues to validate its technology in high-stakes therapeutic environments.
See full Surf Bio company page
